MedTrace Logo

Bioequivalence Study of Moksi® 400mg Tablet and Avelox® 400mg Tablet (Moxifloxacin) Under Fasting Condition in Healthy Adult Pakistani Subjects

NCT05307614 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2022-04-01

No results posted yet for this study

Summary

Single dose, two way crossover Bioequivalence (BE) study to evaluate the comparative bioavailability of moxifloxacin.

Conditions

  • Bioequivalence

Interventions

DRUG

Moksi® 400mg Tablet

Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.

DRUG

Drug: Avelox® 400Mg Tablet

Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.

Sponsors & Collaborators

Principal Investigators

  • Raeefuddin Ahmed, MD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-27
Primary Completion
2019-04-23
Completion
2019-04-27

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05307614 on ClinicalTrials.gov